TruQuick™ Strep B Red
The TruQuick Strep B Red/20T is a rapid visual immunoassay for the qualitative, presumptive detection of Group B Streptococcus (GBS) antigens in specimens taken from vaginal or rectal swaps of pregnant women, or general swabs from newborn. This kit is intended for use as an aid in the diagnosis of Strep B infection.
Group B Streptococci (GBS) or Streptococcus agalactiae are among the most frequent causes of life-threatening infectious in neonates. Between 5% and 30% of all pregnant women are colonized with GBS.1Several recent studies have shown that the intrapartum treatment of GBS-colonized women significantly reduces the incidence of GBS-caused sepsis.2-4 The US Center for Disease Control and Prevention (CDC) recommends routine examination for Group B streptococcus between the 35th and the 37th week of pregnancy. A CDC study has shown that routine examinations is 50% more effective than the use of antibiotics for pregnant women with clinical risk factors. Standard culture methods require 24 to 48 hours, and the results may not be available soon enough for efficient treatment. Thus, methods utilizing more rapid screening techniques are required.
- Finch, R.G., French, G.L., and Phillips, I.; Group B streptococci in the female genital tract; Br. Med. J., 1 (6020) 1245-1247, 1976
- You, M.D., Mason, E.O., Leeds, L.J., Thompson, P.K., Clark, D.J. and Gardner, S.E.; Ampicilin prevents intrapartum transmission of group B streptococcus; JAMA 241 (12) 1245-1247 ,1979
- Boyer, K.M., and Gotoff, S.P.; Prevention of early-onset neonatal group B streptococcal disease with selective intrapartumchemotaxis; N. Eng. J. Med. 314 1665-1669, 1986
- Lim, D.V., Morales, W.J., Walsh, W.J. and Kazanis, D.; Reduction of morbidity and mortility rates for neonatal group B streptococcal disease through early diagnosis and chemoprophylaxis; J. Clin. Microbiol. 23 489-492, 1986